Price (delayed)
$3.21
Market cap
$8.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.69
Enterprise value
$5.84M
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform
There are no recent dividends present for GTBP.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.